Catalyst Pharmaceuticals Stockholders Approve Merger With Angelini Pharma
Catalyst Pharmaceuticals (NASDAQ:CPRX) stockholders approved the company's merger with Angelini Pharma at a special meeting on July 8, 2026. The deal will see Catalyst become a wholly owned subsidiary of Angelini Pharma following the merger between Catalyst and Angelini Cello Inc., a Delaware-based subsidiary of Angelini Pharma.
Topics: corporate_development pharmaceuticals stockholder_vote